The medication joined the two SGLT2 inhibitors already on the market: empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) and dapagliflozin (Farxiga; AstraZeneca). Neither of the selective SGLT2 ...

GlobalData is the parent company of Clinical Trials Arena. Elsewhere in the field of gene therapies, Boehringer Ingelheim has initiated the Phase I/II LENTICLAIR 1 trial of its inhaled treatment for ...

VAXXITEK® HVT+IBD+H5 is a new trivalent vaccine for poultry that offers protection against Marek’s disease, Infectious Bursal Disease and H5 avian influenza in just one shot. VAXXITEK® HVT ...

Credit: Andrey_Popov / Shutterstock. Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced the Phase I/II LENTICLAIR 1 trial of ...

Ingelheim, Germany, 20 February 2025 – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial ...

Rico Nasty is used to the post-tour comedown. She spends weeks, if not months, at a time on the road performing for audiences who restlessly await the days until they can unleash their pent-up ...

Credit: Jo Panuwat D/Shutterstock. The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) for zongertinib to treat unresectable or ...

The company’s lead obesity asset, survodutide, a glucagon/GLP-1 receptor dual agonist partnered with Boehringer Ingelheim, has already advanced into Phase III trials for obesity and metabolic ...

Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved The ...

NexGard® is a flea and tick prevention medication for dogs that was developed by Boehringer Ingelheim ... Minnesota, New Jersey, and Puerto Rico. They make up the second-largest animal health company ...